RICHMOND, Va., April 22, 2025 (GLOBE NEWSWIRE) -- The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions, and ATM managed services, will host a conference call on Monday, May 12, at 4:30 p.m. (ET) to review first-quarter financial results, which will be released after the market close. The conference call can be accessed by calling 888-349-0094 (in the U.S.) or 412-902-0124 (international). Participants should join at least five minutes prior to ...

Core Points - National Bank Holdings Corporation reported a net income of $24.2 million for Q1 2025, a decrease from $28.2 million in Q4 2024 and $31.4 million in Q1 2024, primarily due to a $10.2 million provision expense related to a loan charge-off involving suspected fraud [3][4][14] - The diluted earnings per share for Q1 2025 was $0.63, down from $0.73 in Q4 2024 and $0.82 in Q1 2024 [4][30] - The return on average tangible assets was 1.09% for Q1 2025, compared to 1.23% in Q4 2024 and 1.39% in Q1 2024 [4][14] - The company maintained a solid net interest margin of 3.93%, with a 3.4% growth in fully taxable equivalent net interest income year-over-year [3][5] Financial Performance - Net interest income for Q1 2025 was $88.6 million, down from $92.0 million in Q4 2024, attributed to two fewer business days and a decrease in average earning assets [5][15] - The average total deposits decreased by $111.6 million to $8.3 billion during Q1 2025, while transaction deposits grew by $147.7 million to $7.4 billion [8][18] - Non-interest income increased to $15.4 million in Q1 2025 from $11.1 million in Q4 2024, driven by higher mortgage banking income [9][19] Asset Quality - The company recorded a provision expense for credit losses of $10.2 million in Q1 2025, significantly higher than $2.0 million in Q4 2024, primarily due to the fraud-related charge-off [7][17] - Non-performing loans decreased to 0.45% of total loans, while non-performing assets decreased to 0.46% [7][17] - The allowance for credit losses as a percentage of loans was 1.18% at March 31, 2025, compared to 1.22% at December 31, 2024 [7][17] Capital and Equity - The Common Equity Tier 1 capital ratio was reported at 13.6%, with tangible book value per share increasing by $0.66 to $25.94 during the quarter [3][12] - Shareholders' equity rose by $24.2 million to $1.3 billion, primarily due to retained earnings growth from net income [12][13] Loan Portfolio - Total loans amounted to $7.6 billion as of March 31, 2025, a decrease from $7.8 billion at the end of Q4 2024, with quarterly loan fundings of $255.7 million [6][34] - The weighted average rate on new loans was 7.3%, compared to a weighted average yield of 6.4% on the loan portfolio [6][34]

NYSE Ticker: NBHC DENVER, April 22, 2025 (GLOBE NEWSWIRE) -- National Bank Holdings Corporation (the “Company”) reported: For the quarter(1) For the quarter - adjusted(1)(2) 1Q25 4Q24 1Q24 1Q25 4Q24 1Q24Net income ($000's) $24,231 $< ...

Company Announcement - SiriusPoint Ltd. plans to release its first quarter 2025 financial results after market close on May 5, 2025 [1] - A webcast and conference call to discuss the financial results will be held at 8:30 am (Eastern Time) on May 6, 2025 [1] Access Information - The webcast can be accessed through the Investor Relations section of the company's website [2] - A replay of the conference call will be available immediately after the call [2] Conference Call Details - The conference call can be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) [3] - A replay of the call will be available until 11:59 pm (Eastern Time) on May 20, 2025 [3] Company Overview - SiriusPoint is a global underwriter of insurance and reinsurance, headquartered in Bermuda with offices in major cities [4] - The company has over $2.6 billion in total capital and holds a financial strength rating of A- (Excellent) from AM Best, S&P, and Fitch [4]

Core Viewpoint - Hanmi Financial Corporation reported stable financial performance in Q1 2025, with net income remaining unchanged from the previous quarter, reflecting solid operating results across all business lines and effective expense management [2][3][7]. Financial Performance - Net income for Q1 2025 was $17.7 million, or $0.58 per diluted share, consistent with Q4 2024 [2][7]. - Return on average assets increased to 0.94% from 0.93% in Q4 2024, while return on average equity rose to 8.92% from 8.89% [2][8]. - Net interest income increased by 3.1% to $55.1 million compared to $53.4 million in Q4 2024, driven by lower funding costs and an expanding net interest margin [9][10]. Loan and Deposit Growth - Loans receivable reached $6.28 billion, up 0.5% from Q4 2024, with loan production for Q1 at $345.9 million [7][19]. - Deposits increased by 2.9% to $6.62 billion, supported by new commercial accounts and contributions from newly opened branches [3][7]. - Noninterest-bearing demand deposits constituted 31.2% of total deposits as of March 31, 2025 [7]. Credit Quality and Expenses - Credit loss expense for Q1 was $2.7 million, up from $0.9 million in the previous quarter, with an allowance for credit losses of $70.6 million, or 1.12% of loans [14][19]. - Noninterest expense rose to $35.0 million, primarily due to seasonal increases in salaries and benefits, although overall operating expenses showed a decrease when excluding one-time gains from the previous quarter [15][17]. Noninterest Income - Noninterest income increased by 5.0% to $7.7 million, driven by a significant rise in gains from the sale of SBA loans, which totaled $2.0 million for Q1 2025 [15][16]. - The volume of SBA loans sold increased to $32.2 million from $21.6 million in the previous quarter [15]. Efficiency and Margin - The efficiency ratio improved to 55.7% from 56.8% in Q4 2024, indicating better cost management relative to income [15][17]. - The net interest margin increased by 11 basis points to 3.02%, reflecting a decrease in the cost of interest-bearing deposits [9][12].

Core Points - Abivax is advancing towards key operational milestones in 2025, including the ongoing Phase 3 ABTECT clinical program [3][7] - The Annual General Meeting is scheduled for June 6, 2025, in Paris, France [1][7] - The company aims to complete enrollment for induction trials in Q2 2025, with top-line data expected in Q3 2025 [3][7] - The CEO of Abivax, Marc de Garidel, expressed confidence in the company's long-term value, highlighting a personal investment of approximately 120,000 shares in Q1 2025 [4] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases [5] - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 trials for moderately to severely active ulcerative colitis [5]

Core Points - PennantPark Floating Rate Capital Ltd. amended its credit facility agreement, reducing pricing to SOFR plus 200 basis points from SOFR plus 225 basis points, extending the reinvestment period to August 2028, and extending the maturity date to August 2030 [1][2] - The maximum first lien advance rate increased to 72.5% from 70.0%, while commitments decreased from $736 million to $718 million [1] Company Overview - PennantPark Floating Rate Capital Ltd. is a business development company that primarily invests in U.S. middle-market private companies through floating rate senior secured loans, including first lien secured debt, second lien secured debt, and subordinated debt [4] - The company is managed by PennantPark Investment Advisers, LLC, which manages approximately $10 billion of investible capital and offers a range of financing solutions to middle-market borrowers [5]

Wa'el Hashad Wa'el Hashad, CEO, Longeveron MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Fellow Shareholders, Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Longeve ...

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering regenerative exosomes-based therapies for central nervous system injuries, is pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“Exo-Top”), a wholly owned subsidiary of the Company, and as Vice President, Corporate Development at NurExone. Exo-Top is a U.S.-ba ...

TORRANCE, Calif., April 22, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ: PRTS) will hold a conference call on Tuesday, May 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the first quarter ended March 29, 2025. The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and CFO Ryan Lockwood will host the conference call live via an audio webcast, followed by a question and answer period. To access the conferenc ...